Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resistant prostate cancer in patients being treated with abiraterone and enzalutamide, where the disease can show progression radiographically but not always detected on PSAs or CT scans. Additional topics discussed include next-generation imaging technologies for castrate-resistant prostate cancer, whole body MRI scan imaging software, European imaging standards (where this diagnoses tool is more widely-used), and the cost-effectiveness of performing whole body MRI scans. 

Biography: 

Anwar Padhani, MBBS, FRCP, FRCR  is a Consultant Radiologist and Professor of Cancer Imaging, Mount Vernon Cancer Centre, London, UK.  Dr. Padhani is a leading authority on whole body MRI scans for detecting recurrent, metastatic prostate cancer.  He is known for his work in monitoring castrate-resistant patients for disease progression even when there is no rise in PSA.

Co-interviewers:
John Fortin is a retired Fellow in the Society of Actuaries and a patient advocate
Henry Oat, Patient Coordinator at Desert Medical Imaging and a patient advocate

Related Content: 

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

ASCO 2017: Phase 3 prognostic analysis of the automated bone scan index in men with bone-metastatic castration-resistant prostate cancer

TAT-10: Dosimetry and Biodistribution of Pb203-AR-RMX in Patients with Somatostatin Expressing Neuroendocrine Tumors: A Clinical Exploratory Study

SUO 2017: Advanced Imaging in Prostate Cancer: [18F] FACBC

EAU PCa 17: Patient Tailored Staging